Navigation Links
NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases
Date:10/2/2007

Cambridge, MA October 2, 2007 Phylonix Pharmaceuticals, Inc. today announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for New Models for Eye Diseases will support the Phylonix program over a period of three years.

The eye is a highly conserved organ and the basic structure between human and zebrafish eyes is indistinguishable. In addition, numerous eye diseases have been modeled in zebrafish including choroidal neovascularization, similar to age-related macular degeneration (AMD) in humans; ocular scarring that occurs after surgery for glaucoma; retinopathy induced by diabetes and edema; and ocular ischemia caused by several pathologies.

The funding for this program will be used to further develop our novel, patent pending methods for modeling eye diseases and to identify potential drug candidates, commented Patricia McGrath, Phylonix President and Chief Executive Officer. Our preliminary data show good correlation between results in zebrafish and results in mammals and we are very pleased to receive this Phase II SBIR award from the National Eye Institute.

Phylonix is modeling a number of eye diseases in zebrafish including diabetic retinopathy and AMD, the two leading causes of blindness in adults in the industrialized world. Both conditions involve vascular abnormalities, proliferation and leakage of new blood vessels. Other eye diseases resulting in blindness that Phylonix is modeling in zebrafish include retinopathy of prematurity, a major cause of newborn blindness in premature infants maintained by oxygen supplementation during the postnatal period. This disease involves intense neovascularization of the retina and leads to retinal detachment. Another cause of blindness is corneal neovascularization, which often results from injury and infection in the cornea.

Current mammalian models for ocular neovascularization require lengthy, tedious surgical manipulation and do not always result in improved vision; an alternative rapid, less invasive animal model for studying the process of ocular neovascularization and assessing drug effects will facilitate identification of new therapeutics. As the population ages, the incidence of eye diseases is rapidly increasing and convenient methods for assessing single and combination therapies in whole animals are urgently needed.

Advantages of using zebrafish for compound screening

Laboratory animals are critical for defining the mechanisms of drug activity and for testing therapeutic regimens, however, only a few useful models have been developed. Zebrafish has several important advantages for drug screening: they are small, inexpensive to maintain, and easily bred in large numbers. Zebrafish eggs are externally fertilized and a single mating produces 100-200 eggs. Single embryos can be maintained in fluid volumes as small as 100 microliters for the first six days of development and cultured in microtiter wells. Chemicals can then be added directly to the fish water, permeating the intact embryos. Standard microtiter plate readers can be used for quantitation, making this format particularly attractive for high-throughput drug screening.

Phylonix is developing a family of zebrafish assays with compelling advantages: 1) short assay time, 2) single dosing, 3) small amount of drug required for each test, 4) statistically significant numbers of animals can be assayed for each condition, 5) embryos maintenance during drug delivery is easy, and 6) low cost the estimated cost of each zebrafish assay is less than $100. Chemicals, small molecules, proteins, and nucleic acids such as knock-down reagents can be assessed using the Phylonix zebrafish assays.


'/>"/>

Contact: Edward O'Lear
ed.olear@phylonix.com
617-441-6700
Phylonix
Source:Eurekalert

Related medicine news :

1. Aussie Nobel Prize Winners Receive Their Awards
2. Prestigious Gairdner Awards for medical research in 2006 Goes To Two Yale biologists
3. The President Gives Away National Disability Awards
4. Majority of Padma Awards Go to Doctors from Delhi
5. US, Indian Doctors Bag Thai Medical Awards
6. WHO Awards Prequalification Status to the First UAE Approved Vaccine
7. Bio-Rad Gets Life Science Industry Awards – 200
8. Michael J. Fox Foundation Awards $710,000 to Understanding of Parkinsons Disease Subtypes
9. Ontario Court Awards Compensation To Paralyzed Worker
10. Talwalkars Awards a Record $1 Million Order to Nautilus
11. NIH Awards Emory $3.6 Million for Schizophrenia Gene Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Bionic Sports ... all walks of life, announced it had a successful January ECRM Trade Show in ... in the United States, which allows it to provide its products to all clients ...
(Date:1/20/2017)... ... 20, 2017 , ... International Protein, a company based out of Australia that ... the January ECRM trade show in Hilton Head, SC. , International Protein was ... create a line of products that would elevate her fitness regime. At this ECRM ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... its sugar-free alternative VW+ 002. The drinks have been produced in collaboration with ... to perform during your workout. , After a successful launch in Sweden last ...
(Date:1/20/2017)... ... ... a biographical account following a man who went on to support his country and serve ... in Lynn Haven, Florida and at the age of 5, his family moved to Pensacola ... the Navy and got married right out of boot camp. , He and his ...
(Date:1/20/2017)... ... , ... “Christmas in Suffolk”: a story of love, secrets, and mystery. ... Lafayette, Indiana where she works in a daycare and looks for inspiration in the ... Christian Faith Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical ... MBA as Chief Medical Officer. Dr Weinberg will be based in ... ... more than 17 years as a pharmaceutical and biotech executive with ... the course of his career, he has interfaced with the US ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
Breaking Medicine Technology: